组蛋白去乙酰化酶抑制剂在抗病毒药物研究中的进展  

Research progress of histone deacetylases inhibitors in antiviral drugs discovery

作　　者：许丽 毛念栋 张航[1] 何兴瑞 叶向阳 谢恬[1] XU Li;MAO Nian-dong;ZHANG Hang;HE Xing-rui;YE Xiang-yang;XIE Tian(School of Pharmacy,Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines,Engineering Laboratory of Development and Application of Traditional Chinese Medicines,Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province,Hangzhou Normal University,Hangzhou 311121,China)

机构地区：[1]杭州师范大学药学院,浙江省榄香烯类抗癌中药重点实验室,浙产中药材资源开发与应用浙江省工程实验室,浙江省浙八味等浙产中药材综合利用开发2011协同创新中心,浙江杭州311121

出　　处：《药学学报》2022年第4期917-930,共14页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(82073686,81730108,81973635);杭州市“115”引进国(境)外智力项目计划(20200215,20210120);杭州师范大学(卓越人才计划科研启动基金2019QDL003和校级、院级教改项目);国家科技部外国专家项目(G20200217005,G2021017004)。

摘　　要：组蛋白去乙酰化酶(HDACs)是一类关键的表观遗传修饰酶。目前,已经有5个小分子HDACs抑制剂获批上市,主要应用于抗肿瘤领域。近年来,有关HDACs抑制剂在抗病毒方面的研究越来越多。本文从药物化学的视角,按艾滋病毒(HIV-1)、新型冠状病毒(SARS-CoV-2)、EB病毒(EBV)和其他病毒等分类归纳,系统总结了近年来HDACs抑制剂在辅助抗病毒领域的进展。本综述旨在帮助药学工作者了解掌握HDACs抑制剂在抗病毒方面的最新成果,展望HDACs抑制剂在抗病毒领域应用的挑战和前景。Histone deacetylases(HDACs) are a class of key enzymes that regulate epigenetics. There are 5small-molecule HDACs inhibitors having been approved for anti-cancer therapy on the market. In recent years,there have been more and more studies on the antiviral aspects of HDACs inhibitors. This article classifies viruses into human immunodeficiency virus 1(HIV-1), new coronavirus(SARS-CoV-2), Epstein-Barr virus(EBV) and other viruses, systematically summarizes the recent advances of antiviral effects of the HDACs inhibitors from the perspective of medicinal chemistry. This review aims to provide the researchers the convenience of accessing the latest advances of the antiviral effects of HDACs inhibitors, and to analyze the challenges and prospects of this field in future drug discovery.

关 键 词：组蛋白去乙酰化酶抑制剂 HIV-1 SARS-CoV-2 EBV 

分 类 号：R914[医药卫生—药物化学]